ZyVersa Therapeutics Showcases Lipidomic Findings in Alport Syndrome and DKD, Emphasizing the Importance of Medications to Reduce Harmful Renal Lipid Build-Up and Slow Disease Progression
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 03 2025
0mins
Source: Newsfilter
ZyVersa's VAR 200 Development: ZyVersa Therapeutics is developing Cholesterol Efflux Mediator™ VAR 200 to remove excess cholesterol and lipids from kidney cells, aiming to mitigate renal disease progression by addressing inflammation, fibrosis, and oxidative stress.
Clinical Trials and Market Potential: A Phase 2a clinical trial for VAR 200 in diabetic kidney disease patients has begun, with preliminary results expected by Q4-2025, while the global kidney disease drug market is projected to grow from $18 billion in 2024 to $30 billion by 2034.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
